ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
With just weeks remaining in 2015, C&EN is taking stock of the biggest news and trends in the pharmaceutical industry. The following pages feature the stories that had the most impact—positive or negative—on companies, researchers, investors, and patients.
We take note of the themes that consistently found their way into the headlines, and even the presidential race, this year: the rapidly rising cost of drugs, the pressure for big companies to get even bigger, the promise and peril of the gene-editing technology CRISPR, and the great potential to harness the immune system to quash cancer.
We look at the launch of well-funded biotech companies, many of which were jockeying for lab space in Boston, a city that is emerging as the center of the life sciences universe. And we explore the financial trends that impacted the top 10 drug firms, a list that will get reshuffled if Pfizer’s recently announced deal to acquire Allergan is consummated next year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter